- call +1-201-465-4211
- email sales@marketsandresearch.biz
- Call +1-201-465-4211
- Email: sales@marketsandresearch.biz
As the global economy mends, the 2021 growth of PARP (Poly ADP-Ribose Polymerase) Inhibitor will have significant change from previous year. According to our latest study, the global PARP (Poly ADP-Ribose Polymerase) Inhibitor market size is USD million in 2022 from USD 4584.5 million in 2021, with a change of % between 2021 and 2022. The global PARP (Poly ADP-Ribose Polymerase) Inhibitor market size will reach USD 8506.6 million in 2028, growing at a CAGR of 9.2% over the analysis period.
The United States PARP (Poly ADP-Ribose Polymerase) Inhibitor market is expected at value of US$ million in 2021 and grow at approximately % CAGR during review period. China constitutes a % market for the global PARP (Poly ADP-Ribose Polymerase) Inhibitor market, reaching US$ million by the year 2028. As for the Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period. In APAC, the growth rates of other notable markets (Japan and South Korea) are projected to be at % and % respectively for the next 5-year period.
Global main PARP (Poly ADP-Ribose Polymerase) Inhibitor players cover AstraZeneca, Tesaro, Merck & Co, and Clovis Oncology, etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.
This report presents a comprehensive overview, market shares, and growth opportunities of PARP (Poly ADP-Ribose Polymerase) Inhibitor market by product type, application, key manufacturers and key regions and countries.
Segmentation by type: breakdown data from 2017 to 2022, in Section 2.3; and forecast to 2028 in section 12.6
Lynparza
Zejula
Rubraca
Talzenna
Other
Segmentation by application: breakdown data from 2017 to 2022, in Section 2.4; and forecast to 2028 in section 12.7.
Ovarian Cancer
Breast Cancer
Other
This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The report also presents the market competition landscape and a corresponding detailed analysis of the prominent manufacturers in this market, include
AstraZeneca
Tesaro
Merck & Co
Clovis Oncology
Pfizer
GSK
Zai Lab
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
2 Executive Summary
2.1 World Market Overview
2.1.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Annual Sales 2017-2028
2.1.2 World Current & Future Analysis for PARP (Poly ADP-Ribose Polymerase) Inhibitor by Geographic Region, 2017, 2022 & 2028
2.1.3 World Current & Future Analysis for PARP (Poly ADP-Ribose Polymerase) Inhibitor by Country/Region, 2017, 2022 & 2028
2.2 PARP (Poly ADP-Ribose Polymerase) Inhibitor Segment by Type
2.2.1 Lynparza
2.2.2 Zejula
2.2.3 Rubraca
2.2.4 Talzenna
2.2.5 Other
2.3 PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Type
2.3.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Type (2017-2022)
2.3.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue and Market Share by Type (2017-2022)
2.3.3 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sale Price by Type (2017-2022)
2.4 PARP (Poly ADP-Ribose Polymerase) Inhibitor Segment by Application
2.4.1 Ovarian Cancer
2.4.2 Breast Cancer
2.4.3 Other
2.5 PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Application
2.5.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sale Market Share by Application (2017-2022)
2.5.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue and Market Share by Application (2017-2022)
2.5.3 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sale Price by Application (2017-2022)
3 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor by Company
3.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Breakdown Data by Company
3.1.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Annual Sales by Company (2020-2022)
3.1.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Company (2020-2022)
3.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Annual Revenue by Company (2020-2022)
3.2.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Company (2020-2022)
3.2.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Company (2020-2022)
3.3 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sale Price by Company
3.4 Key Manufacturers PARP (Poly ADP-Ribose Polymerase) Inhibitor Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Location Distribution
3.4.2 Players PARP (Poly ADP-Ribose Polymerase) Inhibitor Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for PARP (Poly ADP-Ribose Polymerase) Inhibitor by Geographic Region
4.1 World Historic PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size by Geographic Region (2017-2022)
4.1.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Annual Sales by Geographic Region (2017-2022)
4.1.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Annual Revenue by Geographic Region
4.2 World Historic PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size by Country/Region (2017-2022)
4.2.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Annual Sales by Country/Region (2017-2022)
4.2.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Annual Revenue by Country/Region
4.3 Americas PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Growth
4.4 APAC PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Growth
4.5 Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Growth
4.6 Middle East & Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Growth
5 Americas
5.1 Americas PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Country
5.1.1 Americas PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Country (2017-2022)
5.1.2 Americas PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Country (2017-2022)
5.2 Americas PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Type
5.3 Americas PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Region
6.1.1 APAC PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Region (2017-2022)
6.1.2 APAC PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Region (2017-2022)
6.2 APAC PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Type
6.3 APAC PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor by Country
7.1.1 Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Country (2017-2022)
7.1.2 Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Country (2017-2022)
7.2 Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Type
7.3 Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor by Country
8.1.1 Middle East & Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Country (2017-2022)
8.1.2 Middle East & Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Country (2017-2022)
8.2 Middle East & Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Type
8.3 Middle East & Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of PARP (Poly ADP-Ribose Polymerase) Inhibitor
10.3 Manufacturing Process Analysis of PARP (Poly ADP-Ribose Polymerase) Inhibitor
10.4 Industry Chain Structure of PARP (Poly ADP-Ribose Polymerase) Inhibitor
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 PARP (Poly ADP-Ribose Polymerase) Inhibitor Distributors
11.3 PARP (Poly ADP-Ribose Polymerase) Inhibitor Customer
12 World Forecast Review for PARP (Poly ADP-Ribose Polymerase) Inhibitor by Geographic Region
12.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size Forecast by Region
12.1.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Forecast by Region (2023-2028)
12.1.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Annual Revenue Forecast by Region (2023-2028)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Forecast by Type
12.7 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Forecast by Application
13 Key Players Analysis
13.1 AstraZeneca
13.1.1 AstraZeneca Company Information
13.1.2 AstraZeneca PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Offered
13.1.3 AstraZeneca PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales, Revenue, Price and Gross Margin (2020-2022)
13.1.4 AstraZeneca Main Business Overview
13.1.5 AstraZeneca Latest Developments
13.2 Tesaro
13.2.1 Tesaro Company Information
13.2.2 Tesaro PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Offered
13.2.3 Tesaro PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales, Revenue, Price and Gross Margin (2020-2022)
13.2.4 Tesaro Main Business Overview
13.2.5 Tesaro Latest Developments
13.3 Merck & Co
13.3.1 Merck & Co Company Information
13.3.2 Merck & Co PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Offered
13.3.3 Merck & Co PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales, Revenue, Price and Gross Margin (2020-2022)
13.3.4 Merck & Co Main Business Overview
13.3.5 Merck & Co Latest Developments
13.4 Clovis Oncology
13.4.1 Clovis Oncology Company Information
13.4.2 Clovis Oncology PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Offered
13.4.3 Clovis Oncology PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales, Revenue, Price and Gross Margin (2020-2022)
13.4.4 Clovis Oncology Main Business Overview
13.4.5 Clovis Oncology Latest Developments
13.5 Pfizer
13.5.1 Pfizer Company Information
13.5.2 Pfizer PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Offered
13.5.3 Pfizer PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales, Revenue, Price and Gross Margin (2020-2022)
13.5.4 Pfizer Main Business Overview
13.5.5 Pfizer Latest Developments
13.6 GSK
13.6.1 GSK Company Information
13.6.2 GSK PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Offered
13.6.3 GSK PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales, Revenue, Price and Gross Margin (2020-2022)
13.6.4 GSK Main Business Overview
13.6.5 GSK Latest Developments
13.7 Zai Lab
13.7.1 Zai Lab Company Information
13.7.2 Zai Lab PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Offered
13.7.3 Zai Lab PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales, Revenue, Price and Gross Margin (2020-2022)
13.7.4 Zai Lab Main Business Overview
13.7.5 Zai Lab Latest Developments
14 Research Findings and Conclusion
List of Tables
Table 1. PARP (Poly ADP-Ribose Polymerase) Inhibitor Annual Sales CAGR by Geographic Region (2017, 2022 & 2028) & ($ millions)
Table 2. PARP (Poly ADP-Ribose Polymerase) Inhibitor Annual Sales CAGR by Country/Region (2017, 2022 & 2028) & ($ millions)
Table 3. Major Players of Lynparza
Table 4. Major Players of Zejula
Table 5. Major Players of Rubraca
Table 6. Major Players of Talzenna
Table 7. Major Players of Other
Table 8. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Type (2017-2022) & (K Units)
Table 9. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Type (2017-2022)
Table 10. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Type (2017-2022) & ($ million)
Table 11. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Type (2017-2022)
Table 12. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sale Price by Type (2017-2022) & (USD/Unit)
Table 13. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Application (2017-2022) & (K Units)
Table 14. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Application (2017-2022)
Table 15. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Application (2017-2022)
Table 16. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Application (2017-2022)
Table 17. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sale Price by Application (2017-2022) & (USD/Unit)
Table 18. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Company (2020-2022) & (K Units)
Table 19. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Company (2020-2022)
Table 20. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Company (2020-2022) ($ Millions)
Table 21. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Company (2020-2022)
Table 22. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sale Price by Company (2020-2022) & (USD/Unit)
Table 23. Key Manufacturers PARP (Poly ADP-Ribose Polymerase) Inhibitor Producing Area Distribution and Sales Area
Table 24. Players PARP (Poly ADP-Ribose Polymerase) Inhibitor Products Offered
Table 25. PARP (Poly ADP-Ribose Polymerase) Inhibitor Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
Table 26. New Products and Potential Entrants
Table 27. Mergers & Acquisitions, Expansion
Table 28. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Geographic Region (2017-2022) & (K Units)
Table 29. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share Geographic Region (2017-2022)
Table 30. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Geographic Region (2017-2022) & ($ millions)
Table 31. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Geographic Region (2017-2022)
Table 32. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Country/Region (2017-2022) & (K Units)
Table 33. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Country/Region (2017-2022)
Table 34. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Country/Region (2017-2022) & ($ millions)
Table 35. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Country/Region (2017-2022)
Table 36. Americas PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Country (2017-2022) & (K Units)
Table 37. Americas PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Country (2017-2022)
Table 38. Americas PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Country (2017-2022) & ($ Millions)
Table 39. Americas PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Country (2017-2022)
Table 40. Americas PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Type (2017-2022) & (K Units)
Table 41. Americas PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Type (2017-2022)
Table 42. Americas PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Application (2017-2022) & (K Units)
Table 43. Americas PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Application (2017-2022)
Table 44. APAC PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Region (2017-2022) & (K Units)
Table 45. APAC PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Region (2017-2022)
Table 46. APAC PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Region (2017-2022) & ($ Millions)
Table 47. APAC PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Region (2017-2022)
Table 48. APAC PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Type (2017-2022) & (K Units)
Table 49. APAC PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Type (2017-2022)
Table 50. APAC PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Application (2017-2022) & (K Units)
Table 51. APAC PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Application (2017-2022)
Table 52. Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Country (2017-2022) & (K Units)
Table 53. Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Country (2017-2022)
Table 54. Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Country (2017-2022) & ($ Millions)
Table 55. Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Country (2017-2022)
Table 56. Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Type (2017-2022) & (K Units)
Table 57. Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Type (2017-2022)
Table 58. Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Application (2017-2022) & (K Units)
Table 59. Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Application (2017-2022)
Table 60. Middle East & Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Country (2017-2022) & (K Units)
Table 61. Middle East & Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Country (2017-2022)
Table 62. Middle East & Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Country (2017-2022) & ($ Millions)
Table 63. Middle East & Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Country (2017-2022)
Table 64. Middle East & Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Type (2017-2022) & (K Units)
Table 65. Middle East & Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Type (2017-2022)
Table 66. Middle East & Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Application (2017-2022) & (K Units)
Table 67. Middle East & Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Application (2017-2022)
Table 68. Key Market Drivers & Growth Opportunities of PARP (Poly ADP-Ribose Polymerase) Inhibitor
Table 69. Key Market Challenges & Risks of PARP (Poly ADP-Ribose Polymerase) Inhibitor
Table 70. Key Industry Trends of PARP (Poly ADP-Ribose Polymerase) Inhibitor
Table 71. PARP (Poly ADP-Ribose Polymerase) Inhibitor Raw Material
Table 72. Key Suppliers of Raw Materials
Table 73. PARP (Poly ADP-Ribose Polymerase) Inhibitor Distributors List
Table 74. PARP (Poly ADP-Ribose Polymerase) Inhibitor Customer List
Table 75. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Forecast by Region (2023-2028) & (K Units)
Table 76. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Forecast by Region
Table 77. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Forecast by Region (2023-2028) & ($ millions)
Table 78. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share Forecast by Region (2023-2028)
Table 79. Americas PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Forecast by Country (2023-2028) & (K Units)
Table 80. Americas PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Forecast by Country (2023-2028) & ($ millions)
Table 81. APAC PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Forecast by Region (2023-2028) & (K Units)
Table 82. APAC PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Forecast by Region (2023-2028) & ($ millions)
Table 83. Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Forecast by Country (2023-2028) & (K Units)
Table 84. Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Forecast by Country (2023-2028) & ($ millions)
Table 85. Middle East & Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Forecast by Country (2023-2028) & (K Units)
Table 86. Middle East & Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Forecast by Country (2023-2028) & ($ millions)
Table 87. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Forecast by Type (2023-2028) & (K Units)
Table 88. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share Forecast by Type (2023-2028)
Table 89. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Forecast by Type (2023-2028) & ($ Millions)
Table 90. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share Forecast by Type (2023-2028)
Table 91. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Forecast by Application (2023-2028) & (K Units)
Table 92. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share Forecast by Application (2023-2028)
Table 93. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Forecast by Application (2023-2028) & ($ Millions)
Table 94. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share Forecast by Application (2023-2028)
Table 95. AstraZeneca Basic Information, PARP (Poly ADP-Ribose Polymerase) Inhibitor Manufacturing Base, Sales Area and Its Competitors
Table 96. AstraZeneca PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Offered
Table 97. AstraZeneca PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2022)
Table 98. AstraZeneca Main Business
Table 99. AstraZeneca Latest Developments
Table 100. Tesaro Basic Information, PARP (Poly ADP-Ribose Polymerase) Inhibitor Manufacturing Base, Sales Area and Its Competitors
Table 101. Tesaro PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Offered
Table 102. Tesaro PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2022)
Table 103. Tesaro Main Business
Table 104. Tesaro Latest Developments
Table 105. Merck & Co Basic Information, PARP (Poly ADP-Ribose Polymerase) Inhibitor Manufacturing Base, Sales Area and Its Competitors
Table 106. Merck & Co PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Offered
Table 107. Merck & Co PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2022)
Table 108. Merck & Co Main Business
Table 109. Merck & Co Latest Developments
Table 110. Clovis Oncology Basic Information, PARP (Poly ADP-Ribose Polymerase) Inhibitor Manufacturing Base, Sales Area and Its Competitors
Table 111. Clovis Oncology PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Offered
Table 112. Clovis Oncology PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2022)
Table 113. Clovis Oncology Main Business
Table 114. Clovis Oncology Latest Developments
Table 115. Pfizer Basic Information, PARP (Poly ADP-Ribose Polymerase) Inhibitor Manufacturing Base, Sales Area and Its Competitors
Table 116. Pfizer PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Offered
Table 117. Pfizer PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2022)
Table 118. Pfizer Main Business
Table 119. Pfizer Latest Developments
Table 120. GSK Basic Information, PARP (Poly ADP-Ribose Polymerase) Inhibitor Manufacturing Base, Sales Area and Its Competitors
Table 121. GSK PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Offered
Table 122. GSK PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2022)
Table 123. GSK Main Business
Table 124. GSK Latest Developments
Table 125. Zai Lab Basic Information, PARP (Poly ADP-Ribose Polymerase) Inhibitor Manufacturing Base, Sales Area and Its Competitors
Table 126. Zai Lab PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Offered
Table 127. Zai Lab PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2022)
Table 128. Zai Lab Main Business
Table 129. Zai Lab Latest Developments
List of Figures
Figure 1. Picture of PARP (Poly ADP-Ribose Polymerase) Inhibitor
Figure 2. PARP (Poly ADP-Ribose Polymerase) Inhibitor Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Growth Rate 2017-2028 (K Units)
Figure 7. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth Rate 2017-2028 ($ Millions)
Figure 8. PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Region (2021 & 2028) & ($ millions)
Figure 9. Product Picture of Lynparza
Figure 10. Product Picture of Zejula
Figure 11. Product Picture of Rubraca
Figure 12. Product Picture of Talzenna
Figure 13. Product Picture of Other
Figure 14. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Type in 2021
Figure 15. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Type (2017-2022)
Figure 16. PARP (Poly ADP-Ribose Polymerase) Inhibitor Consumed in Ovarian Cancer
Figure 17. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market: Ovarian Cancer (2017-2022) & (K Units)
Figure 18. PARP (Poly ADP-Ribose Polymerase) Inhibitor Consumed in Breast Cancer
Figure 19. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market: Breast Cancer (2017-2022) & (K Units)
Figure 20. PARP (Poly ADP-Ribose Polymerase) Inhibitor Consumed in Other
Figure 21. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market: Other (2017-2022) & (K Units)
Figure 22. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Application (2017-2022)
Figure 23. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Application in 2021
Figure 24. PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market by Company in 2021 ($ Million)
Figure 25. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Company in 2021
Figure 26. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Geographic Region (2017-2022)
Figure 27. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Geographic Region in 2021
Figure 28. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Region (2017-2022)
Figure 29. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Country/Region in 2021
Figure 30. Americas PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales 2017-2022 (K Units)
Figure 31. Americas PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue 2017-2022 ($ Millions)
Figure 32. APAC PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales 2017-2022 (K Units)
Figure 33. APAC PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue 2017-2022 ($ Millions)
Figure 34. Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales 2017-2022 (K Units)
Figure 35. Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue 2017-2022 ($ Millions)
Figure 36. Middle East & Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales 2017-2022 (K Units)
Figure 37. Middle East & Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue 2017-2022 ($ Millions)
Figure 38. Americas PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Country in 2021
Figure 39. Americas PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Country in 2021
Figure 40. United States PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth 2017-2022 ($ Millions)
Figure 41. Canada PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth 2017-2022 ($ Millions)
Figure 42. Mexico PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth 2017-2022 ($ Millions)
Figure 43. Brazil PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth 2017-2022 ($ Millions)
Figure 44. APAC PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Region in 2021
Figure 45. APAC PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Regions in 2021
Figure 46. China PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth 2017-2022 ($ Millions)
Figure 47. Japan PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth 2017-2022 ($ Millions)
Figure 48. South Korea PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth 2017-2022 ($ Millions)
Figure 49. Southeast Asia PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth 2017-2022 ($ Millions)
Figure 50. India PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth 2017-2022 ($ Millions)
Figure 51. Australia PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth 2017-2022 ($ Millions)
Figure 52. Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Country in 2021
Figure 53. Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Country in 2021
Figure 54. Germany PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth 2017-2022 ($ Millions)
Figure 55. France PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth 2017-2022 ($ Millions)
Figure 56. UK PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth 2017-2022 ($ Millions)
Figure 57. Italy PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth 2017-2022 ($ Millions)
Figure 58. Russia PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth 2017-2022 ($ Millions)
Figure 59. Middle East & Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Country in 2021
Figure 60. Middle East & Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Country in 2021
Figure 61. Egypt PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth 2017-2022 ($ Millions)
Figure 62. South Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth 2017-2022 ($ Millions)
Figure 63. Israel PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth 2017-2022 ($ Millions)
Figure 64. Turkey PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth 2017-2022 ($ Millions)
Figure 65. GCC Country PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth 2017-2022 ($ Millions)
Figure 66. Manufacturing Cost Structure Analysis of PARP (Poly ADP-Ribose Polymerase) Inhibitor in 2021
Figure 67. Manufacturing Process Analysis of PARP (Poly ADP-Ribose Polymerase) Inhibitor
Figure 68. Industry Chain Structure of PARP (Poly ADP-Ribose Polymerase) Inhibitor
Figure 69. Channels of Distribution
Figure 70. Distributors Profiles
Please feel free to write an email to us or to use our electronic ticketing system.
